Best cumulative response to bosutinib
| Response, n (%) . | IM + DAS resistant (n = 37) . | IM + DAS intolerant (n = 50) . | IM + NI resistant (n = 27) . | IM + DAS ± NI (n = 4)* . | Total (n = 118) . |
|---|---|---|---|---|---|
| Median follow-up, mo (range) | 20.0 (2.7-51.3) | 34.5 (0.3-56.2) | 23.0 (7.1-54.0) | 34.5 (22.8-40.0) | 28.5 (0.3-56.2) |
| Hematologic response† | |||||
| Evaluable patients | 37 | 49 | 26 | 4 | 116 |
| Complete response | 23 (62) | 39 (80) | 20 (77) | 3 (75) | 85 (73) |
| Hematologic response among patients with no baseline CHR | |||||
| Evaluable patients | 22 | 24 | 20 | 2 | 68 |
| Complete response | 11 (50) | 16 (67) | 15 (75) | 2 (100) | 44 (65) |
| Cytogenetic response‡ | |||||
| Evaluable patients | 35 | 43 | 26 | 4 | 108 |
| Major response | 11 (31) | 13 (30) | 9 (35) | 2 (50) | 35 (32) |
| Complete response | 5 (14) | 12 (28) | 7 (27) | 2 (50) | 26 (24) |
| Partial response | 6 (17) | 1 (2) | 2 (8) | 0 | 9 (8) |
| Minor response | 0 | 4 (9) | 2 (8) | 0 | 6 (6) |
| Molecular response§ | |||||
| Evaluable patients | 35 | 48 | 19 | 3 | 105 |
| Major response | 1 (3) | 12 (25) | 2 (11) | 1 (33) | 16 (15) |
| Complete response | 0 | 9 (19) | 2 (11) | 1 (33) | 12 (11) |
| Response, n (%) . | IM + DAS resistant (n = 37) . | IM + DAS intolerant (n = 50) . | IM + NI resistant (n = 27) . | IM + DAS ± NI (n = 4)* . | Total (n = 118) . |
|---|---|---|---|---|---|
| Median follow-up, mo (range) | 20.0 (2.7-51.3) | 34.5 (0.3-56.2) | 23.0 (7.1-54.0) | 34.5 (22.8-40.0) | 28.5 (0.3-56.2) |
| Hematologic response† | |||||
| Evaluable patients | 37 | 49 | 26 | 4 | 116 |
| Complete response | 23 (62) | 39 (80) | 20 (77) | 3 (75) | 85 (73) |
| Hematologic response among patients with no baseline CHR | |||||
| Evaluable patients | 22 | 24 | 20 | 2 | 68 |
| Complete response | 11 (50) | 16 (67) | 15 (75) | 2 (100) | 44 (65) |
| Cytogenetic response‡ | |||||
| Evaluable patients | 35 | 43 | 26 | 4 | 108 |
| Major response | 11 (31) | 13 (30) | 9 (35) | 2 (50) | 35 (32) |
| Complete response | 5 (14) | 12 (28) | 7 (27) | 2 (50) | 26 (24) |
| Partial response | 6 (17) | 1 (2) | 2 (8) | 0 | 9 (8) |
| Minor response | 0 | 4 (9) | 2 (8) | 0 | 6 (6) |
| Molecular response§ | |||||
| Evaluable patients | 35 | 48 | 19 | 3 | 105 |
| Major response | 1 (3) | 12 (25) | 2 (11) | 1 (33) | 16 (15) |
| Complete response | 0 | 9 (19) | 2 (11) | 1 (33) | 12 (11) |
IM indicates imatinib; DAS, dasatinib; and NI, nilotinib.
Includes 3 patients who previously received all 3 inhibitors and 1 patient with NI intolerance.
Evaluable patients had a baseline disease assessment. Patients with CHR at baseline were evaluable for hematologic response and were considered responders if they maintained their response at 2 consecutive post-baseline assessments ≥ 4 weeks apart.
Evaluable patients had a baseline disease assessment. Patients with CCyR at baseline were considered nonresponders for assessment of cytogenetic response.
Because of logistical constraints, patients from sites in China, India, Russia, and South Africa were not assessed for molecular response. MMR indicates ≥ 3 log reduction from standardized baseline Bcr-Abl:Abl ratio; and CMR, undetectable Bcr-Abl, with a sensitivity of ≥ 5 log. Molecular response was not assessed according to the International Scale.